Skip Ribbon Commands
Skip to main content

MASTER DAPT Study

MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus standard DAPT regimen.

05/10/2021 -  


About MASTER DAPT Study

MASTER DAPT is the largest multi-center randomized controlled study on the use of short duration of dual antiplatelet therapy (DAPT) in high bleeding risk patients following stenting procedures with Ultimaster™/Ultimaster™TanseiTM drug-eluting bioresorbable polymer stents (DES).

MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe. The study is managed by global CROs and data management group (CERC, Paris, France, Cardialysis, Rotterdam, The Netherlands, CV quest. Co. Ltd., Tokyo, Japan and CTU, Bern, Switzerland).



MASTER DAPT Study Highlights



MASTER DAPT Study Design - A true randomized DAPT study



MASTER DAPT has met the three coprimary endpoints

  • 1-month DAPT after implantation of Ultimaster™ family DES does not increase the ischemic risk, but reduces the bleeding risk in high bleeding risk patients

  • Patients with acute coronary syndrome, and patients who underwent complex or multivessel PCI were included

  • Supports reduction of DAPT duration to 1 month after implantation of Ultimaster™ family DES in a broad cohort of high-bleeding risk patients

  • MASTER DAPT included patients at high bleeding risk who had undergone implantation of Ultimaster™ family stent; Results may not extend to patients who are not at high bleeding risk or who receive other stent types.



Abbreviated DAPT non-inferior to standard DAPT in terms of NACE

Net adverse clinical events (NACE, a composite of death from any cause, myocardial infarction, stroke, or major bleeding)*



Abbreviated DAPT non-inferior to standard DAPT in terms of MACCE

Major adverse cardiac and cerebral events* (MACCE, a composite of death from any cause, myocardial infarction, or stroke)



Abbreviated DAPT superior to standard DAPT in terms of bleeding

Major or clinically relevant non-major bleeding* (MCB)




Publications on MASTER DAPT

DualAntiplatelet Therapy after PCI in Patients at High Bleeding Risk. Marco Valgimigli, M.D., Ph.D et al. The New England Journal of Medicine, August 28, 2021, DOI: 10.1056/NEJMoa2108749

Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Pieter C. Smits et al. Circulation, August 29, 2021, 10.1161/CIRCULATIONAHA.121.056680



The Ultimaster Clinical Program – Power of n 

The UltimasterTM clinical program included more than 50,000 patients covering 16 CE-marked indications. Learn more